Business is booming for Emergent BioSolutions as it has assisted in the country’s push to create COVID-19 treatments and vaccines. Emergent is developing two plasma-based treatments for COVID-19 and has partnered with four companies on vaccine candidates. It is additionally partnering with the Federal Government to develop and manufacture COVID-19 vaccines. As a result of this wave of new business, the company is hiring approximately 300 new employees in Baltimore and Rockville.
Emergent is based in Gaithersburg, but the manufacturing of its COVID-19 products is taking place at facilities in Pigtown/Carroll-Camden Industrial Area (Camden), Bayview in Baltimore, and Rockville.
Miko Neri, senior director of corporate communications for Emergent, told SouthBMore.com they are looking to hire about 200 full-time employees and 100 part-time employees across the three Maryland manufacturing facilities. The jobs are in manufacturing, sales, administration, and support.
Emergent is partnering with Johnson & Johnson, Novavax, Vaxvart, and AstraZeneca on COVID-19 vaccine candidates. The private and Federal Government partnerships for Emergent are valued at more than $864 million (the financial details were not disclosed for all of the partnerships). Emergent said the Federal Government partnership with Biomedical Advanced Research and Development Authority (BARDA) will result in an approximately $85.5-million investment into its Camden and Rockville facilities.
Last year, Emergent began a $50-million expansion of its Camden facility at 1111 S. Paca St. Neri said the new investment in Camden as a result of the BARDA partnership will be an “investment in capacity” within the existing footprint of the Camden facility. Emergent acquired the Camden facility in 2015.